Drug · CHEMBL2364655
Comparisons in its trials35
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
1 to 20 of 35
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Evolocumab vs Placebo: serious adverse events | 3,410 of 13,769 | 3,404 of 13,756 | 27,525 | NCT01764633 | Trial comparisons |
| Evolocumab in Parent Study vs Placebo in Parent Study: deaths from any cause | 287 of 2,500 | 309 of 2,535 | 5,035 | NCT02867813 | Trial comparisons |
Evolocumab Once Every 2 Weeks (Q2W) or Once a Month (QM) in Parent Study vs Placebo Once Every 2 Weeks (Q2W) or Once a Month (QM) in Parent Study: Number of Participants Who Experienced an Adverse Event | 2,084 of 2,499 | 2,144 of 2,532 | 5,031 | NCT02867813 | Trial comparisons |
| Evolocumab in Parent Study vs Placebo in Parent Study: serious adverse events | 1,045 of 2,499 | 1,077 of 2,532 | 5,031 | NCT02867813 | Trial comparisons |
| Evolocumab vs Placebo: serious adverse events | 212 of 983 | 204 of 990 | 1,973 | NCT02207634 | Trial comparisons |
| Evolocumab in Parent Study vs Placebo in Parent Study: deaths from any cause | 51 of 855 | 35 of 745 | 1,600 | NCT03080935 | Trial comparisons |
Evolocumab Once Every 2 Weeks (Q2W) or Once Every Month (QM) in Parent Study vs Placebo Once Every 2 Weeks (Q2W) or Once Every Month (QM) in Parent Study: Number of Participants Who Experienced an Adverse Event | 810 of 854 | 686 of 745 | 1,599 | NCT03080935 | Trial comparisons |
| Evolocumab in Parent Study vs Placebo in Parent Study: serious adverse events | 410 of 854 | 323 of 745 | 1,599 | NCT03080935 | Trial comparisons |
| Evolocumab vs Placebo: serious adverse events | 135 of 484 | 142 of 484 | 968 | NCT01813422 | Trial comparisons |
| Evolocumab vs Placebo: serious adverse events | 33 of 599 | 13 of 302 | 901 | NCT01516879 | Trial comparisons |
| Evolocumab vs Placebo: deaths from any cause | 1 of 280 | 0 of 141 | 421 | NCT02739984 | Trial comparisons |
| Evolocumab vs Placebo: serious adverse events | 14 of 280 | 2 of 141 | 421 | NCT02739984 | Trial comparisons |
| Evolocumab vs Ezetimibe: serious adverse events | 9 of 145 | 10 of 73 | 218 | NCT01984424 | Trial comparisons |
| Evolocumab AMD vs Evolocumab AI/Pen: serious adverse events | 0 of 82 | 1 of 82 | 164 | NCT01879319 | Trial comparisons |
| Evolocumab vs Placebo: deaths from any cause | 0 of 82 | 2 of 82 | 164 | NCT03570697 | Trial comparisons |
| Evolocumab vs Placebo: serious adverse events | 13 of 80 | 16 of 81 | 161 | NCT03570697 | Trial comparisons |
| EvoMab 420 mg SC QM vs Placebo SC QM: deaths from any cause | 0 of 105 | 0 of 53 | 158 | NCT02392559 | Trial comparisons |
| EvoMab 420 mg SC QM vs Placebo SC QM: serious adverse events | 1 of 104 | 0 of 53 | 157 | NCT02392559 | Trial comparisons |
| Evolocumab PFS vs Evolocumab AI/Pen: serious adverse events | 3 of 75 | 2 of 74 | 149 | NCT01849497 | Trial comparisons |
| Evolocumab 420 mg QM vs Placebo QM: deaths from any cause | 0 of 65 | 0 of 64 | 129 | NCT02729025 | Trial comparisons |
pipelines-2026-09-18-0.3.1
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL2364655/comparisons